Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003158928 | Thyroid | ATC | cell-substrate adhesion | 195/6293 | 363/18723 | 1.58e-15 | 1.17e-13 | 195 |
GO:005165625 | Thyroid | ATC | establishment of organelle localization | 206/6293 | 390/18723 | 2.62e-15 | 1.84e-13 | 206 |
GO:190285017 | Thyroid | ATC | microtubule cytoskeleton organization involved in mitosis | 95/6293 | 147/18723 | 1.29e-14 | 7.62e-13 | 95 |
GO:001081029 | Thyroid | ATC | regulation of cell-substrate adhesion | 128/6293 | 221/18723 | 8.74e-14 | 4.57e-12 | 128 |
GO:000705222 | Thyroid | ATC | mitotic spindle organization | 80/6293 | 120/18723 | 1.27e-13 | 6.46e-12 | 80 |
GO:015011527 | Thyroid | ATC | cell-substrate junction organization | 70/6293 | 101/18723 | 2.29e-13 | 1.09e-11 | 70 |
GO:000705122 | Thyroid | ATC | spindle organization | 109/6293 | 184/18723 | 7.99e-13 | 3.46e-11 | 109 |
GO:001063926 | Thyroid | ATC | negative regulation of organelle organization | 179/6293 | 348/18723 | 3.74e-12 | 1.50e-10 | 179 |
GO:0007044111 | Thyroid | ATC | cell-substrate junction assembly | 65/6293 | 95/18723 | 4.11e-12 | 1.62e-10 | 65 |
GO:000716329 | Thyroid | ATC | establishment or maintenance of cell polarity | 122/6293 | 218/18723 | 8.46e-12 | 3.16e-10 | 122 |
GO:0007160111 | Thyroid | ATC | cell-matrix adhesion | 128/6293 | 233/18723 | 1.49e-11 | 5.41e-10 | 128 |
GO:000726524 | Thyroid | ATC | Ras protein signal transduction | 172/6293 | 337/18723 | 2.25e-11 | 7.96e-10 | 172 |
GO:000166731 | Thyroid | ATC | ameboidal-type cell migration | 228/6293 | 475/18723 | 3.72e-11 | 1.22e-09 | 228 |
GO:015011627 | Thyroid | ATC | regulation of cell-substrate junction organization | 51/6293 | 71/18723 | 5.01e-11 | 1.63e-09 | 51 |
GO:0048041110 | Thyroid | ATC | focal adhesion assembly | 59/6293 | 87/18723 | 7.05e-11 | 2.23e-09 | 59 |
GO:0001952110 | Thyroid | ATC | regulation of cell-matrix adhesion | 78/6293 | 128/18723 | 2.09e-10 | 6.15e-09 | 78 |
GO:001097523 | Thyroid | ATC | regulation of neuron projection development | 212/6293 | 445/18723 | 4.16e-10 | 1.14e-08 | 212 |
GO:005189325 | Thyroid | ATC | regulation of focal adhesion assembly | 47/6293 | 66/18723 | 4.64e-10 | 1.25e-08 | 47 |
GO:009010925 | Thyroid | ATC | regulation of cell-substrate junction assembly | 47/6293 | 66/18723 | 4.64e-10 | 1.25e-08 | 47 |
GO:0010811210 | Thyroid | ATC | positive regulation of cell-substrate adhesion | 73/6293 | 123/18723 | 4.12e-09 | 9.37e-08 | 73 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP4 | SNV | Missense_Mutation | novel | c.3131A>G | p.Asn1044Ser | p.N1044S | P27816 | protein_coding | deleterious(0.01) | possibly_damaging(0.641) | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
MAP4 | SNV | Missense_Mutation | | c.71A>G | p.Asp24Gly | p.D24G | P27816 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP4 | insertion | In_Frame_Ins | novel | c.3410_3411insCTTACTGTCCAAAACTACAAGGACAGTGACAGTTCTGACAGG | p.Gln1137delinsHisLeuLeuSerLysThrThrArgThrValThrValLeuThrGly | p.Q1137delinsHLLSKTTRTVTVLTG | P27816 | protein_coding | | | TCGA-A8-A0A2-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
MAP4 | insertion | Nonsense_Mutation | novel | c.2692_2693insACTGCATATAGTGATGGAGAAAGATCACAGT | p.Pro898HisfsTer4 | p.P898Hfs*4 | P27816 | protein_coding | | | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD |
MAP4 | SNV | Missense_Mutation | novel | c.1241N>T | p.Ser414Leu | p.S414L | P27816 | protein_coding | deleterious(0) | possibly_damaging(0.656) | TCGA-DS-A5RQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
MAP4 | SNV | Missense_Mutation | novel | c.2122N>G | p.Gln708Glu | p.Q708E | P27816 | protein_coding | deleterious(0.04) | benign(0.328) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAP4 | SNV | Missense_Mutation | | c.3155G>A | p.Gly1052Glu | p.G1052E | P27816 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-EK-A2RK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP4 | SNV | Missense_Mutation | | c.2968G>T | p.Gly990Trp | p.G990W | P27816 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-MU-A5YI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
MAP4 | SNV | Missense_Mutation | novel | c.2544G>C | p.Lys848Asn | p.K848N | P27816 | protein_coding | deleterious(0) | probably_damaging(0.928) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
MAP4 | SNV | Missense_Mutation | novel | c.478G>T | p.Ala160Ser | p.A160S | P27816 | protein_coding | tolerated(0.13) | benign(0.039) | TCGA-5M-AATE-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |